The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care

HIV Clinical Trial

Official title:

The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02474992
• Other study ID #: OHR006
• Status: Completed
• Phase: N/A
• Start date: January 2016
• Est. completion date: June 2019

Study information

• Verified date: August 2019
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this randomized controlled trial is to compare a social network-based behavioral intervention known as microclinics to standard HIV clinical care alone in helping patients receiving HIV care on Mfangano, Remba and Ringiti Islands, Kenya remain adherent to clinic appointments. The study is designed to evaluate the effectiveness of microclinics on reducing gaps in clinical care, HIV viral load and HIV-related stigma, compared to standard HIV clinical care alone. By doing this research study, the investigators hope to learn whether microclinics are a useful social strategy for improving delivery of HIV treatment in rural Kenya.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 304
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be currently receiving combination antiretroviral therapy (cART) or co-trimoxozole prophylaxis from one of the eligible study clinics:

• Is currently in care at study baseline, defined as having =1 medical care visit to receive medications (cART or prophylaxis) during the six months preceeding initiation of study enrollment, OR

• Initiates pre-ART or ART care for the first time at a study clinic during the six month study recruitment period, OR

• Transfers from a clinic outside the study area and receives pre-ART or ART care for the first time from a study clinic during the six month recruitment period

• Participants become eligible for study inclusion on the 4th day following a missed clinic appointment, provided the patient has not transferred care to another clinic prior to the 4th day, moved outside the study area or died. Participants who miss a study visit by >3 days but return to clinic before recruitment takes place are still eligible for study enrollment. Missed visits must have occurred within the previous 90 days at the time of eligibility assessment to meet this inclusion criteria.

• Must currently reside on Mfangano, Remba or Ringiti Island.

• Must be conversant with one of the commonly spoken languages within the study area (i.e. DhoLuo, Swahili or English; prior experience indicates that this represents >99% of the adult population).

• Must be =18 years of age as of the date of study eligibility.

Exclusion Criteria:

• Eligible participants who reside in the Mfangano East sub-location will be excluded from participation in this study. Many of these patients have already participated in the microclinic intervention as part of the Mfangano Island Healthy Network Impact Study.

• Participants planning on moving permanently out of the study area within the next six months will be excluded.

• Participants who, should they be randomized to the intervention arm, would be unwilling to participate in a microclinic will be excluded from study enrollment.

Related Conditions & MeSH terms

• HIV

Intervention

Behavioral:
• Microclinic
Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.

Locations

Country	Name	City	State
Kenya	Ekialo Kiona Center	Mfangano Island	Homa Bay County

Sponsors (4)

Lead Sponsor	Collaborator
University of California, San Francisco	Kenya Medical Research Institute, Microclinic International, Organic Health Response

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disengagement from care	Incidence of 90-day absence from care following a missed appointment	12 months
Primary	Disengagement from care	Proportion of time eligible for HIV care that patient is adherent to clinic appointment schedules. Calculated by subtracting the sum of all gaps in care from the total time eligible for care, and dividing by total time eligible for care. Gaps in care are defined as the number of days between a missed appointment and subsequent return to any clinic in the study area to access HIV care.	12 months
Secondary	Virologic suppression	Proportion of patients who are virologically suppressed 12 months after randomization	12 months
Secondary	HIV-related stigma	Reduction in stigma as compared to baseline, measured by the Earnshaw HIV Stigma Framework	12 months
Secondary	Re-engagement in care	Incidence of re-engagement in care following missed visit at time of study enrollment	12 months